Huapont Life Sciences Co.,Ltd. (SHE:002004)
China · Delayed Price · Currency is CNY 5.57
+0.13 (2.39%)
Feb 6, 2026, 12:35 PM CST
Huapont Life Sciences Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Jan '21 Jan 1, 2021 |
Net Income | -139.15 | -298.99 | 302.12 | 433.48 | 667.81 | 651.73 |
Depreciation & Amortization | 960.96 | 960.96 | 891.24 | 800.23 | 747.68 | 696.31 |
Other Amortization | 94.61 | 94.61 | 87.44 | 87.87 | 84.44 | 83.09 |
Loss (Gain) From Sale of Assets | -3.75 | -3.75 | -28.11 | 8.78 | -8.73 | -5.73 |
Asset Writedown & Restructuring Costs | 816.15 | 816.15 | 297.12 | 535.85 | 153.83 | 27.68 |
Loss (Gain) From Sale of Investments | 194.06 | 194.06 | -8.72 | -436.65 | -308.53 | -255.77 |
Provision & Write-off of Bad Debts | 20.68 | 20.68 | 7.61 | 7.26 | 19.31 | -35.95 |
Other Operating Activities | 449.04 | 362.92 | 740.56 | 1,112 | 719.48 | 848.65 |
Change in Accounts Receivable | -914.12 | -914.12 | -587.98 | 59.61 | -1,040 | -128.78 |
Change in Inventory | 317.41 | 317.41 | -201.92 | -154.58 | -456.09 | 142.21 |
Change in Accounts Payable | 153.83 | 153.83 | 190.68 | 1.46 | 645.38 | 306.92 |
Change in Other Net Operating Assets | 20.3 | 20.3 | -10.67 | 21.44 | 33.32 | 67.87 |
Operating Cash Flow | 1,871 | 1,625 | 1,589 | 2,408 | 1,270 | 2,373 |
Operating Cash Flow Growth | 24.35% | 2.25% | -33.99% | 89.65% | -46.49% | 13.96% |
Capital Expenditures | -711.57 | -956.27 | -1,284 | -1,131 | -1,256 | -1,231 |
Sale of Property, Plant & Equipment | 53.05 | 35.69 | 72.28 | 35.92 | 59.06 | 29.83 |
Cash Acquisitions | - | - | -3.95 | -15.84 | -41.4 | - |
Divestitures | -0.45 | 2.23 | - | - | 1.31 | -0.02 |
Investment in Securities | -370.24 | -413.96 | -321.82 | 584.97 | 301.12 | -685.5 |
Other Investing Activities | 144.1 | 187.13 | -212.1 | -30.37 | 145.91 | 126.58 |
Investing Cash Flow | -885.11 | -1,145 | -1,750 | -556.49 | -790.43 | -1,760 |
Short-Term Debt Issued | - | 253.64 | 561.7 | - | 15.4 | - |
Long-Term Debt Issued | - | 8,073 | 8,558 | 7,038 | 9,437 | 12,247 |
Total Debt Issued | 7,240 | 8,327 | 9,120 | 7,038 | 9,452 | 12,247 |
Short-Term Debt Repaid | - | -259.26 | -369.66 | -309.13 | -1,509 | -1,628 |
Long-Term Debt Repaid | - | -7,642 | -8,071 | -7,898 | -10,279 | -11,984 |
Total Debt Repaid | -8,153 | -7,901 | -8,441 | -8,207 | -11,788 | -13,612 |
Net Debt Issued (Repaid) | -912.75 | 425.9 | 678.89 | -1,169 | -2,336 | -1,365 |
Common Dividends Paid | -668.89 | -754.37 | -756.28 | -854.41 | -859.41 | -943.09 |
Other Financing Activities | -19.75 | -355.77 | 73.73 | 653.38 | 2,991 | 2,068 |
Financing Cash Flow | -1,601 | -684.24 | -3.65 | -1,370 | -203.77 | -239.57 |
Foreign Exchange Rate Adjustments | 24.74 | 27.84 | 0.64 | 7.26 | 11.06 | -30.13 |
Net Cash Flow | -590.51 | -176.29 | -163.26 | 488.36 | 286.48 | 342.75 |
Free Cash Flow | 1,160 | 669.02 | 305.35 | 1,277 | 13.19 | 1,142 |
Free Cash Flow Growth | 194.93% | 119.10% | -76.08% | 9579.95% | -98.84% | 75.99% |
Free Cash Flow Margin | 9.79% | 5.73% | 2.63% | 9.65% | 0.11% | 10.50% |
Free Cash Flow Per Share | 0.59 | 0.34 | 0.15 | 0.65 | 0.01 | 0.58 |
Cash Income Tax Paid | 529.97 | 457.41 | 570.87 | 277.96 | 437.81 | 344.62 |
Levered Free Cash Flow | 413.23 | 130.53 | 471.25 | 1,290 | 122.24 | 646.93 |
Unlevered Free Cash Flow | 607.39 | 349.26 | 686.07 | 1,562 | 410.78 | 997.6 |
Change in Working Capital | -521.36 | -521.36 | -699.78 | -141.15 | -805.67 | 362.71 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.